Streamlining Gastroenterology Prior Authorizations with Cognizant TriZetto Integration

For gastroenterology practices, navigating prior authorizations, particularly when interacting with payers via platforms like Cognizant TriZetto, presents unique operational challenges. Klivira automates these complex workflows, ensuring efficient processing for critical GI treatments and procedures.

Revenue cycle directors and prior authorization coordinators in gastroenterology face a high volume of complex prior authorization requests, especially for biologics and advanced procedures. Integrating a robust automation platform with systems like Cognizant TriZetto is crucial for reducing administrative burden, improving turnaround times, and minimizing costly denials. Klivira's intelligent automation streamlines the entire prior authorization lifecycle.

The Specifics of Gastroenterology Prior Authorization Burden

Gastroenterology requires prior authorization for a wide array of services, from high-cost biologics used in inflammatory bowel disease (IBD) to advanced imaging and endoscopic procedures. The continuous nature of chronic disease management, such as for Crohn's disease and ulcerative colitis, means recurring PA cycles. Klivira's integration with systems like Cognizant TriZetto ensures these high-volume requests are managed efficiently, adhering to payer-specific requirements.

Key Prior Authorization Triggers in GI Practice

**IBD Biologics**: Agents like Humira, Stelara, Skyrizi, and Entyvio require stringent PA, often with step therapy and re-authorization protocols.
**Hepatitis C Direct-Acting Antivirals**: Drugs such as Epclusa and Mavyret have specific PA pathways based on genotype and prior treatment history.
**Advanced Imaging**: MRCP, MR enterography, and CT enterography for IBD assessment frequently trigger PA.
**Endoscopic Procedures**: Capsule endoscopy (CPT 91110), small-bowel enteroscopy, and specific ERCP/EUS indications often require prior approval.
**Specialty Drugs for Functional GI Disorders**: Medications like Viberzi, Motegriety, Linzess, and Trulance for IBS-D/C and chronic constipation.

Navigating Payer Interactions via Cognizant TriZetto for GI PAs

As a prominent clearinghouse and payer platform, Cognizant TriZetto facilitates a significant volume of prior authorization submissions and responses. Klivira's platform is engineered to seamlessly integrate with EMR systems and communicate effectively with payer channels, including those managed or accessed through platforms like TriZetto. This ensures that the structured clinical data required for GI PAs—from diagnosis codes to detailed treatment plans—is accurately transmitted and tracked.

Addressing GI-Specific Documentation and Denial Challenges

Gastroenterology prior authorizations are often denied due to missing or inadequate documentation, particularly regarding step therapy compliance for biologics, disease severity scores (e.g., Mayo score for UC, CDAI for Crohn's), and pre-screening results (TB, hepatitis). Klivira's intelligent system leverages ACG and AGA guidelines to auto-populate forms and flag missing information, reducing common denial reasons such as biosimilar substitution requirements or fibrosis-stage documentation gaps for Hep C DAAs.

Klivira's Automation Capabilities for Gastroenterology Workflows

**Guideline-Aware Logic**: Incorporates ACG/AGA guidelines for IBD biologic sequencing and treatment status classification.
**Comprehensive Hep C DAA Workflow**: Manages genotype, fibrosis stage, and drug-interaction documentation requirements.
**Periodic Re-authorization Management**: Automates the ongoing PA burden for chronic-treatment IBD biologics.
**Medical-vs-Pharmacy Benefit Routing**: Intelligently routes PA requests based on the administration mode of biologic agents.
**EMR Integration**: Connects with leading EMRs via SMART on FHIR to extract necessary clinical data, minimizing manual data entry.

Optimizing Prior Authorization Exchange with Clearinghouses like TriZetto

Klivira streamlines the exchange of prior authorization requests and responses by leveraging standard protocols like X12 278 and ePA. For payers utilizing platforms such as Cognizant TriZetto, Klivira ensures that GI-specific documentation, including detailed clinical notes and lab results, is accurately packaged and submitted electronically. This reduces manual portal interactions and provides a unified view of PA status across all payer channels, regardless of their underlying platform.

Frequently asked questions

How does Klivira handle the high volume of IBD biologic re-authorizations?

Klivira's platform includes a dedicated workflow for chronic-treatment IBD biologics, automating periodic re-authorization cycles. It tracks renewal dates, prompts for necessary updated documentation (e.g., disease response scores), and prepares submissions to payers, including those processed through clearinghouses like Cognizant TriZetto, well in advance to prevent treatment delays.

Can Klivira differentiate between medical and pharmacy benefit PAs for GI drugs?

Yes, Klivira intelligently routes prior authorization requests based on whether a biologic agent is provider-administered (medical benefit) or self-administered (pharmacy benefit). This is critical in gastroenterology for IBD drugs, ensuring the correct payer channel is engaged, whether it's an X12 278 submission or an NCPDP SCRIPT ePA.

What specific GI documentation does Klivira automate for submission via platforms like Cognizant TriZetto?

Klivira automates the collection and submission of critical GI documentation, including diagnosis confirmations, disease severity assessments (Mayo score, CDAI), prior conventional therapy trials, TB/hepatitis screening results, and fibrosis staging for Hep C DAAs. This data is structured for efficient transmission to payers, including those using Cognizant TriZetto for PA processing.

How does Klivira help reduce denials for GI procedures like capsule endoscopy?

Klivira's system is configured with payer-specific medical necessity criteria for procedures like capsule endoscopy. It prompts for required prior workup documentation (e.g., upper GI series, EGD) and ensures the indication meets payer policy, significantly reducing denials related to insufficient prior evaluation or inappropriate-use criteria often seen in submissions through clearinghouses like Cognizant TriZetto.

Does Klivira support step therapy requirements for GI prior authorizations?

Absolutely. Klivira incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, ensuring that submissions accurately reflect prior conventional therapy trials or biosimilar substitution requirements. This proactive compliance helps avoid denials from payers, regardless of whether the PA request is submitted directly or via a clearinghouse partner like Cognizant TriZetto.